UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

Molecular cancer, 2011-04, Vol.10 (1), p.35-35, Article 35

2011

Volltextzugriff (PDF)

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

The lancet oncology, 2015-03, Vol.16 (3), p.257-265

2015

Volltextzugriff (PDF)

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Journal of clinical oncology, 2015-03, Vol.33 (9), p.1000-1007

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1095-1102

2019

Volltextzugriff (PDF)

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2052-2059

2011

Volltextzugriff (PDF)

Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer

Psycho-oncology (Chichester, England), 2014-11, Vol.23 (11), p.1318-1322

2014

Volltextzugriff (PDF)

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9002-9002

2018

Volltextzugriff (PDF)

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

The lancet oncology, 2014-02, Vol.15 (2), p.191-200

2014

Volltextzugriff (PDF)

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301

2018

Volltextzugriff (PDF)

Criteria of evidence to move potential chemopreventive agents into late phase clinical trials

Current drug targets, 2011-12, Vol.12 (13), p.1983-1988

2011

Volltextzugriff (PDF)

Systemic Issues in Small Cell Lung Cancer

Current problems in cancer, 2012-05, Vol.36 (3), p.131-155

2012

Volltextzugriff (PDF)

Reply to A. Stenzinger et al

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2824-2824

2015

Volltextzugriff (PDF)

Young Male with Fanconi Anemia and EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-11, Vol.9 (11), p.e83-e85

2014

Volltextzugriff (PDF)

From platinum compounds to targeted therapies in advanced thoracic malignancies

Anticancer research, 2014-01, Vol.34 (1), p.477-482

2014

Volltextzugriff (PDF)

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study

Clinical cancer research, 2014-11, Vol.20 (21), p.5392-5402

2014

Volltextzugriff (PDF)

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-10, Vol.9 (10), p.e75-e78

2014

Volltextzugriff (PDF)

Targeted therapies Importance of patient selection for EGFR TKIs in lung cancer

Nature reviews. Clinical oncology, 2010-07, Vol.7 (7), p.360-362

2010

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9047-9047

2018

Volltextzugriff (PDF)

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis

Journal of thoracic oncology, 2012-11, Vol.7 (11), p.1707-1712

2012

Volltextzugriff (PDF)

Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS8584-TPS8584

2017

Volltextzugriff (PDF)

Neuroendocrine ACTH-Producing Tumor of the Thymus—Experience with 12 Patients over 25 Years

The journal of clinical endocrinology and metabolism, 2012-07, Vol.97 (7), p.2223-2230

2012

Volltextzugriff (PDF)

Importance of patient selection for EGFR TKIs in lung cancer

Nature reviews. Clinical oncology, 2010-07, Vol.7 (7), p.360-362

2010

Volltextzugriff (PDF)

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib

Clinical cancer research, 2011-03, Vol.17 (5), p.1190-1199

2011

Volltextzugriff (PDF)

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.108-115

2017

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(48)
Berichte
(2)

Sprache

Englisch
(50)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(20)
Oncology
(17)
Male
(14)
Female
(12)
Aged
(11)
Lung Neoplasms - Drug Therapy
(11)
Middle Aged
(10)
Antineoplastic Agents - Therapeutic Use
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Adult
(7)
Treatment Outcome
(7)
Lung Cancer
(6)
Lung Neoplasms - Pathology
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(5)
Lung Neoplasms - Genetics
(5)
Mutation
(5)
Animals
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Criteria of evidence to move potential chemopreventive agents into late phase clinical trials

Systemic Issues in Small Cell Lung Cancer

Reply to A. Stenzinger et al

Young Male with Fanconi Anemia and EGFR-Mutant Non–Small-Cell Lung Cancer

From platinum compounds to targeted therapies in advanced thoracic malignancies

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Targeted therapies Importance of patient selection for EGFR TKIs in lung cancer

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)

Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis

Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133)

Neuroendocrine ACTH-Producing Tumor of the Thymus—Experience with 12 Patients over 25 Years

Importance of patient selection for EGFR TKIs in lung cancer

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

Suchergebnisse filtern